Viromed Medical AG

Latest Results (06.10.2025):

Viromed Medical AG reported its first half of 2025 financial results, achieving consolidated revenues of EUR 2.4 million and a net loss of EUR 0.8 million. The company made significant progress in product development, strategic acquisitions, and expanding partnerships, setting a strong foundation for future growth.

Strategic Acquisitions and Partnerships

Viromed expanded its portfolio through the acquisition of pharmedix GmbH, enhancing its offerings in medicine, nutrition, and cosmetics. Additionally, a collaboration with relyon plasma GmbH ensured the series production of innovative cold plasma products ViroCAP® and PulmoPlas®.

Clinical Development Achievements

Initial clinical results for PulmoPlas® in treating ventilator-associated pneumonia (VAP) demonstrated significant potential. Preclinical studies from Hannover Medical School further validated the medical benefits of cold plasma therapy, highlighting its ability to prevent thousands of deaths annually.

Financial Performance

Consolidated revenues reached EUR 2.4 million in the first half of 2025, with a net loss of EUR 0.8 million primarily due to expenses related to the market launch of ViroCAP® and PulmoPlas®. The company’s equity stood at EUR 6.6 million, reflecting an equity ratio of 39.9% as of June 30, 2025.

Future Growth Prospects

Viromed projects substantial revenue growth for the full year 2025, with expectations to increase revenues from EUR 1.37 million in 2024 to between EUR 8 million and EUR 10 million. The company anticipates a slightly positive financial result, driven by the operational performance of the newly acquired pharmedix GmbH.